MedPath

Antihypertensive Treatment in Acute Cerebral Hemorrhage-II

Not Applicable
Conditions
Cerebral Hemorrhage
Registration Number
JPRN-UMIN000006526
Lead Sponsor
niversity of Minnesota National Cerebral and Cardiovascular Center
Brief Summary

We conducted a multicenter trial where eligible subjects with ICH were randomized to intensive (<140 mm Hg) and standard (<180 mm Hg) SBP reduction in a 1:1 ratio <4.5h. The primary outcome of death and disability was ascertained at 3-M post randomization. Compared with standard SBP reduction, intensive SBP reduction in patients with ICH did not lower the rate of death and disability despite achieving a small magnitude reduction in hematoma expansion.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
1000
Inclusion Criteria

Not provided

Exclusion Criteria

1.ICH is due to previously known neoplasms, AVM, or aneurysms 2.Intracerebral hematoma considered to be related to trauma 3.ICH located in infratentorial regions such as pons or cerebellum 4.IVH associated with intraparenchymal hemorrhage and blood completely fills one lateral ventricle or more than half of both ventricles 5.Patient to receive immediate surgical evacuation 6.Current pregnancy, parturition within previous 30 days or active lactation 7.Use of warfarin within the last 5 days and INR >4 8.A platelet count less than 50,000/mm3 9.Known sensitivity to nicardipine 10.Pre-morbid disability requiring assistance in ambulation or activities of daily living 11.Subjects living will precludes aggressive ICU management 12.Subject is currently participating in another interventional clinical trial

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Death or disability, defined by modified Rankin scale (mRS) of 4-6 at 3 m following treatment.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath